TOKYO, Nov 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment“Rozebalamin® for Injection25 mg” (mecobalamin) has been launched in Japan ...
Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment“Rozebalamin® for Injection 25 mg” (mecobalamin ...
April 25, 2013-Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has decided to establish a new parenteral facility (below, "New Plant") on a lot ...